Relapsed Refractory Myeloma clinical trials

Explore recruiting relapsed refractory myeloma clinical trials.

Recruiting relapsed refractory myeloma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

Spain, Italy, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Relapsed Refractory Myeloma trials by city

Relapsed Refractory Myeloma clinical trials

Recruiting relapsed refractory myeloma studies right now

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

CAR-T in Relapsed/Refractory Multiple Myeloma

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Also recruiting in Europe

A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

Relapsed Refractory Myeloma trials by city

Other conditions